Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 193

1.

The value of urinary fibrin/fibrinogen degradation products as tumor markers in urothelial carcinoma.

Jayachandran S, Unni Mooppan MM, Wax SH, Kim H.

J Urol. 1984 Jul;132(1):21-3.

PMID:
6726955
[PubMed - indexed for MEDLINE]
2.

[Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].

Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.

Arch Esp Urol. 2002 Jan-Feb;55(1):41-9. Spanish.

PMID:
11957750
[PubMed - indexed for MEDLINE]
3.

Prognostic value of urinary fibrinogen degradation products in bladder carcinoma.

Alsabti EA.

Eur Surg Res. 1979;11(3):185-90.

PMID:
510327
[PubMed - indexed for MEDLINE]
4.

Urinary fibrin/fibrinogen degradation products in transitional cell carcinoma of the bladder.

Ewing R, Tate GM, Hetherington JW.

Br J Urol. 1987 Jan;59(1):53-8.

PMID:
3828688
[PubMed - indexed for MEDLINE]
5.

Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.

Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL.

J Urol. 1996 Aug;156(2 Pt 1):363-7.

PMID:
8683680
[PubMed - indexed for MEDLINE]
6.

A correlative study on urinary cytology and FDP with cystoscopy and pathology in the urinary bladder cancers.

Tanahashi T, Matsumura Y, Ohmori H, Tanaka T.

Acta Med Okayama. 1978 Jun;32(2):139-46.

PMID:
150199
[PubMed - indexed for MEDLINE]
7.

[Urine cytology and urine markers. Significance for clinical practice].

Tritschler S, Zaak D, Knuechel R, Stief CG.

Urologe A. 2006 Nov;45(11):W1441-7; quiz W1448. German.

PMID:
17063350
[PubMed - indexed for MEDLINE]
8.

Further study of fibrinogen degradation products in bladder cancer detection.

Wajsman Z, Williams PD, Greco J, Murphy GP.

Urology. 1978 Dec;12(6):659-61.

PMID:
741544
[PubMed - indexed for MEDLINE]
9.

The efficacy of urinary cytology in the detection of recurrent bladder tumours.

Baltaci S, Süzer O, Ozer G, Bedük Y, Göğüş O.

Int Urol Nephrol. 1996;28(5):649-53.

PMID:
9061424
[PubMed - indexed for MEDLINE]
10.

Human complement factor H related protein test for monitoring bladder cancer.

Raitanen MP, Marttila T, Nurmi M, Ala-Opas M, Nieminen P, Aine R, Tammela TL; Finnbladder Group.

J Urol. 2001 Feb;165(2):374-7.

PMID:
11176376
[PubMed - indexed for MEDLINE]
11.

Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer.

Raitanen MP, Kaasinen E, Lukkarinen O, Kauppinen R, Viitanen J, Liukkonen T, Tammela TL; Finnbladder Group.

Urology. 2001 Apr;57(4):680-4.

PMID:
11306380
[PubMed - indexed for MEDLINE]
12.

Diagnostic efficacy of the combination of urine cytology, urine analysis and history in the follow-up of bladder carcinoma.

Meuleman EJ, Delaere KP.

Br J Urol. 1988 Aug;62(2):150-3.

PMID:
3408887
[PubMed - indexed for MEDLINE]
13.

Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.

Gilbert SM, Veltri RW, Sawczuk A, Shabsigh A, Knowles DR, Bright S, O'Dowd GJ, Olsson CA, Benson MC, Sawczuk IS.

Urology. 2003 Mar;61(3):539-43.

PMID:
12639642
[PubMed - indexed for MEDLINE]
14.

A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.

Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E.

BJU Int. 2001 Nov;88(7):692-701.

PMID:
11890239
[PubMed - indexed for MEDLINE]
15.

Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.

Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.

Cancer Detect Prev. 2000;24(4):364-8.

PMID:
11059567
[PubMed - indexed for MEDLINE]
16.

The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.

Raitanen MP; FinnBladder Group.

World J Urol. 2008 Feb;26(1):45-50. doi: 10.1007/s00345-007-0230-3. Epub 2008 Jan 8.

PMID:
18180926
[PubMed - indexed for MEDLINE]
17.

Evaluation of biological markers in bladder cancer.

Wajsman Z, Merrin CE, Chu TM, Moore RH, Murphy GP.

J Urol. 1975 Dec;114(6):879-93.

PMID:
1195467
[PubMed - indexed for MEDLINE]
18.

[Urinary cytology in cases of bladder cancer: a critical evaluation].

Rathert P.

Urologe A. 2003 Jul;42(7):908-11. Epub 2003 Mar 26. Review. German.

PMID:
12898033
[PubMed - indexed for MEDLINE]
19.

Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?

Raica M, Miclea F, Ioiart I, Minciu R, Drăgan P.

Rom J Morphol Embryol. 1998 Jan-Dec;44(1-4):173-8.

PMID:
15678859
[PubMed - indexed for MEDLINE]
20.

[Tumor markers for bladder cancer: up-to-date study by the Kiel Tumor Bank].

Hautmann S, Eggers J, Meyhoff H, Melchior D, Munk A, Hamann M, Naumann M, Braun PM, Jünemann KP.

Urologe A. 2007 Nov;46(11):1508-13. German.

PMID:
17932643
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk